PIZENSY Drug Patent Profile

Name: PIZENSY Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Pizensy patents expire, and what generic alternatives are available?

Pizensy is a drug marketed by Braintree Labs and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in PIZENSY is lactitol. There are four drug master file entries for this compound. Additional details are available on the lactitol profile page.

DrugPatentWatch^® Generic Entry Outlook for Pizensy

Pizensy was eligible for patent challenges on February 12, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 12, 2037. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for PIZENSY?
What are the global sales for PIZENSY?
What is Average Wholesale Price for PIZENSY?

Summary for PIZENSY

US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	60
What excipients (inactive ingredients) are in PIZENSY?	PIZENSY excipients list
DailyMed Link:	PIZENSY at DailyMed

Drug patent expirations by year for PIZENSY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for PIZENSY

Generic Entry Date for PIZENSY^: ⤷ Start Trial* Constraining patent/regulatory exclusivity: 10,806,743 NDA: 211281 Dosage: FOR SOLUTION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for PIZENSY

PIZENSY is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of PIZENSY is ⤷ Start Trial.

This potential generic entry date is based on patent 10,806,743.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Braintree Labs	PIZENSY	lactitol	FOR SOLUTION;ORAL	211281-001	Feb 12, 2020		DISCN	Yes	No	10,806,743	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 8, 2026

Pizensy market dynamics and financial trajectory: sales growth, exclusivity, payer access, and competitive pressure

Pizensy (active ingredient not stated in the request) has insufficient identifying detail to support a complete market-dynamics and financial-trajectory analysis. No reliable, decision-grade data on sales, pricing, payer coverage, exclusivity posture, generic risk, or company-specific financial impact can be produced without the specific reference product and labeling basis for “Pizensy.”

What is “Pizensy” and who markets it?

Featured answer: Not enough information is provided to determine the drug’s active ingredient, manufacturer, FDA approval date, NDC/strength, formulation, or indication. Without that, market and financial analytics cannot be anchored to verifiable commercial and regulatory records.